BioSpace News Archive

AIDS Healthcare Foundation (AHF) enthusiastically endorses the Medicare Negotiation and Competitive Licensing Act, two identical bills introduced today in the House of Representatives by Congressman Lloyd Doggett (D-TX) and at least 103 co-sponsors, and in the United States Senate by Senator Sherrod Brown (D-OH).

Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, is pleased to announce that its common shares have been approved to list on The Nasdaq Capital Market and is expected to begin trading under its existing symbol (ZYXI) on February 12, 2019.

CStone Pharmaceutical and IMPACT Therapeutics, Inc. jointly announced that an Investigational New Drug filing has been accepted by the National Medical Products Administration for the combination of CStone’s fully-human anti-PD-L1 monoclonal antibody CS1001 with IMPACT’s PARP inhibitor IMP4297 for multiple tumor types.

Allergy & ENT Associates a provider of exemplary care in Greater Houston since 1957, including our office located in Kingwood, Texas.

Encompass Health Corporation reported its results of operations for the fourth quarter ended December 31, 2018.

Company to Host Conference Call on Thursday, February 21, 2019 at 1:30 p.m. PT / 4:30 p.m. ET

Results from multiple studies of the investigational therapy avalglucosidase alfa in patients with Pompe disease were presented this week during the 15th Annual WORLDSymposium™ in Orlando, Florida

Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the fourth quarter 2018 on Thursday, February 21 at 4:30 p.m. ET / 1:30 p.m. PT.

Alkermes plc will host a conference call and webcast presentation at 8:30 a.m. ET on Thursday, Feb. 14, 2019, to discuss the company’s fourth quarter and year-end 2018 financial results.

InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular diseases, today announced that new U.S. patents have been issued by the U.S. Patent and Trademark Office (USPTO).